1 ng agents, recombinant interferon alpha, and anagrelide.

2 ons for the monitoring of patients receiving anagrelide.

3                      Hydroxyurea (62.8%) and anagrelide (35.4%) were the primary agents used to treat

4 re was no significant difference between the anagrelide and hydroxyurea group regarding incidences of

5 erferon or pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreducti

6                                              Anagrelide as a selective platelet-lowering agent is not

7 ion system, the efficacy and tolerability of anagrelide compared with hydroxyurea were investigated i

8 ll performance by hydroxyurea, compared with anagrelide, in a recent randomized study.

9                                              Anagrelide is a novel platelet-lowering agent that has r

10 oncluded that long-term treatment of ET with anagrelide is associated with decreased reporting of ini

11 effectively lowered by treatment with either anagrelide or hydroxyurea.

12 n hemoglobin levels in patients treated with anagrelide (P < .0001), but not in those receiving hydro

13 thrombosis, in patients with ET treated with anagrelide plus aspirin compared to hydroxyurea plus asp

14 developed increased bone marrow reticulin on anagrelide showed regression of fibrosis when switched t

15 e specimens in patients randomly assigned to anagrelide showed significantly greater increases in ret

16 nsitive to therapy with hydroxyurea, but not anagrelide, than those without the JAK2 mutation.

17 33 responding patients, 27 (82%) remained on anagrelide therapy for a median of 10.8 years (range, 7

18   These data suggest that patients receiving anagrelide therapy should undergo surveillance bone marr

19 tients (17 to 48 years) with ET who received anagrelide treatment before 1992.

20 n additional information regarding long-term anagrelide use.

21  Confirmatory proof of the noninferiority of anagrelide was achieved after 6 months using the primary

22                                              Anagrelide was used in place of hydroxyurea in two patie